Journal of Central Nervous System Disease最新文献

筛选
英文 中文
Bartonella henselae, Babesia odocoilei and Babesia divergens-like MO-1 infection in the brain of a child with seizures, mycotoxin exposure and suspected Rasmussen's encephalitis.
IF 2.6
Journal of Central Nervous System Disease Pub Date : 2025-03-12 eCollection Date: 2025-01-01 DOI: 10.1177/11795735251322456
Edward B Breitschwerdt, Ricardo G Maggi, Cynthia Robveille, Emily Kingston
{"title":"<i>Bartonella henselae</i>, <i>Babesia odocoilei</i> and <i>Babesia divergens</i>-like MO-1 infection in the brain of a child with seizures, mycotoxin exposure and suspected Rasmussen's encephalitis.","authors":"Edward B Breitschwerdt, Ricardo G Maggi, Cynthia Robveille, Emily Kingston","doi":"10.1177/11795735251322456","DOIUrl":"10.1177/11795735251322456","url":null,"abstract":"<p><strong>Background: </strong>In conjunction with more sensitive culture and molecular diagnostic testing modalities, simultaneous or sequential infection with more than 1 vector borne zoonotic pathogen is being increasingly documented in human patients. On a frequent basis, many people are exposed to apparently healthy, but infected, domestic and wild animals, the arthropod vectors with which these animals have co-evolved, and the bacterial, protozoal and other pathogens for which various animals are reservoirs. Unsuspected zoonotic transmission by scratch, bite, or vector exposures can result in chronic, indolent, or potentially life-threatening infections.</p><p><strong>Methods: </strong>In December 2016, at 2 years of age, a male child residing in Ontario, Canada received facial scratches from a feral cat. In August 2018, seizures began 8 days after the child developed a focal, suspected insect bite rash. In June 2019, potential mold toxicity in the child's bedroom was assessed by fungal culture and urinary mycotoxin assays. Beginning in January 2022, <i>Bartonella</i> spp. serology (indirect fluorescent antibody assays), polymerase chain reaction (PCR) amplification, DNA sequencing, and enrichment blood and brain cultures were used on a research basis to assess <i>Bartonella</i> spp. bloodstream and central nervous system (brain biopsy) infection. In 2024, using recently developed PCR and DNA sequencing targets, <i>Babesia</i> species infection was retrospectively assessed due to the rash observed in 2018.</p><p><strong>Results: </strong>Although there was historical cat and suspected tick exposures, serological testing for <i>Bartonella henselae</i> and <i>Borrelia burgdorferi</i> were repeatedly negative. Sequential neurodiagnostic testing partially supported a diagnosis of Rasmussen's encephalitis. Astrogliosis was the only brain biopsy histopathological abnormality. <i>Bartonella henselae</i> DNA was amplified and sequenced from enrichment cultures of brain tissue. Retrospectively, <i>Babesia odocoilei</i> and <i>Babesia divergens</i>-like MO-1 infections were confirmed by amplification and sequencing of DNA extracted from enrichment blood cultures processed in January 2022, from blood and brain tissue cultures in June 2022, and blood in January and June 2023.</p><p><strong>Conclusions: </strong>Infection with <i>B</i>. <i>henselae</i>, <i>B</i>. <i>odocoilei</i>, and <i>B</i>. <i>divergens</i>-like MO-1, complicated by mycotoxin exposure, created a complex clinical scenario for this child, his parents, and his doctors.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"17 ","pages":"11795735251322456"},"PeriodicalIF":2.6,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gut microbiota: A new window for the prevention and treatment of neuropsychiatric disease.
IF 2.6
Journal of Central Nervous System Disease Pub Date : 2025-02-21 eCollection Date: 2025-01-01 DOI: 10.1177/11795735251322450
Yali Tang, Yizhu Zhang, Chen Chen, Ying Cao, Qiaona Wang, Chuanfeng Tang
{"title":"Gut microbiota: A new window for the prevention and treatment of neuropsychiatric disease.","authors":"Yali Tang, Yizhu Zhang, Chen Chen, Ying Cao, Qiaona Wang, Chuanfeng Tang","doi":"10.1177/11795735251322450","DOIUrl":"10.1177/11795735251322450","url":null,"abstract":"<p><p>Under normal physiological conditions, gut microbiota and host mutually coexist. They play key roles in maintaining intestinal barrier integrity, absorption, and metabolism, as well as promoting the development of the central nervous system (CNS) and emotional regulation. The dysregulation of gut microbiota homeostasis has attracted significant research interest, specifically in its impact on neurological and psychiatric disorders. Recent studies have highlighted the important role of the gut- brain axis in conditions including Alzheimer's Disease (AD), Parkinson's Disease (PD), and depression. This review aims to elucidate the regulatory mechanisms by which gut microbiota affect the progression of CNS disorders via the gut-brain axis. Additionally, we discuss the current research landscape, identify gaps, and propose future directions for microbial interventions against these diseases. Finally, we provide a theoretical reference for clinical treatment strategies and drug development for AD, PD, and depression.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"17 ","pages":"11795735251322450"},"PeriodicalIF":2.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and outcomes of mild stroke patients undergoing reperfusion therapy: A meta-analysis and SAFE recommendations for optimal management.
IF 2.6
Journal of Central Nervous System Disease Pub Date : 2025-02-12 eCollection Date: 2025-01-01 DOI: 10.1177/11795735251314881
Pathmesh Rajeswaran, Bella B Huasen, Peter Stanwell, Murray C Killingsworth, Sonu M M Bhaskar
{"title":"Prevalence and outcomes of mild stroke patients undergoing reperfusion therapy: A meta-analysis and SAFE recommendations for optimal management.","authors":"Pathmesh Rajeswaran, Bella B Huasen, Peter Stanwell, Murray C Killingsworth, Sonu M M Bhaskar","doi":"10.1177/11795735251314881","DOIUrl":"10.1177/11795735251314881","url":null,"abstract":"<p><strong>Background: </strong>Mild acute ischemic stroke (AIS), characterized by a National Institutes of Health Stroke Scale (NIHSS) score of 5 or less, can lead to significant long-term disabilities. Reperfusion therapies like intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT) are commonly used in AIS, but their efficacy and safety in mild stroke cases remain unclear.</p><p><strong>Objectives: </strong>This meta-analysis aims to clarify the prevalence of mild AIS and evaluate the outcomes of reperfusion therapy, specifically IVT and EVT, in terms of functional recovery, mortality, stroke recurrence, and adverse events such as symptomatic intracerebral hemorrhage (sICH), intracerebral hemorrhage (ICH), and early neurological deterioration (END).</p><p><strong>Design: </strong>A meta-analysis was conducted following PRISMA guidelines to combine and assess the results of independent studies examining the use of reperfusion therapies in patients with mild AIS.</p><p><strong>Data sources and methods: </strong>A systematic search of PubMed, Embase, and Cochrane databases was performed. Studies assessing mild AIS prevalence and the outcomes of reperfusion therapy were included. Random effects modelling was applied to evaluate associations between reperfusion therapy and clinical outcomes at 90 days.</p><p><strong>Results: </strong>Fifty-six studies, including 474 778 patients, were analyzed. The pooled prevalence of mild stroke was 54% among all AIS cases, 29% in IVT-treated patients, and 9% in EVT-treated patients. Reperfusion therapy was associated with significantly increased odds of sICH (OR 2.92), ICH (OR 2.20), and END (OR 2.37). However, no significant association was found with excellent functional outcomes (OR 0.93), good functional outcomes (OR 0.91), mortality (OR 1.14), or stroke recurrence (OR 0.93) at 90 days. Variations were observed between different reperfusion subgroups.</p><p><strong>Conclusion: </strong>Mild AIS is prevalent, and reperfusion therapy in these cases is linked to higher rates of adverse events without a clear benefit in functional outcomes or mortality. These findings support the need for selective reperfusion therapy in mild stroke patients. The proposed SAFE framework-Selective use of IVT, Assessment of individual factors, Focus on EVT for large vessel occlusion (LVO), and Establishment of region-specific guidelines-may help guide clinical decisions. Further research should refine patient selection criteria and explore adjunctive therapies.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"17 ","pages":"11795735251314881"},"PeriodicalIF":2.6,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcriptomics profiling of Parkinson's disease progression subtypes reveals distinctive patterns of gene expression.
IF 2.6
Journal of Central Nervous System Disease Pub Date : 2025-01-27 eCollection Date: 2025-01-01 DOI: 10.1177/11795735241286821
Carlo Fabrizio, Andrea Termine, Carlo Caltagirone
{"title":"Transcriptomics profiling of Parkinson's disease progression subtypes reveals distinctive patterns of gene expression.","authors":"Carlo Fabrizio, Andrea Termine, Carlo Caltagirone","doi":"10.1177/11795735241286821","DOIUrl":"10.1177/11795735241286821","url":null,"abstract":"<p><strong>Background: </strong>Parkinson's Disease (PD) varies widely among individuals, and Artificial Intelligence (AI) has recently helped to identify three disease progression subtypes. While their clinical features are already known, their gene expression profiles remain unexplored.</p><p><strong>Objectives: </strong>The objectives of this study were (1) to describe the transcriptomics characteristics of three PD progression subtypes identified by AI, and (2) to evaluate if gene expression data can be used to predict disease subtype at baseline.</p><p><strong>Design: </strong>This is a retrospective longitudinal cohort study utilizing the Parkinson's Progression Markers Initiative (PPMI) database.</p><p><strong>Methods: </strong>Whole blood RNA-Sequencing data underwent differential gene expression analysis, followed by multiple pathway analyses. A Machine Learning (ML) classifier, namely XGBoost, was trained using data from multiple modalities, including gene expression values.</p><p><strong>Results: </strong>Our study identified differentially expressed genes (DEGs) that were uniquely associated with Parkinson's disease (PD) progression subtypes. Importantly, these DEGs had not been previously linked to PD. Gene-pathway analysis revealed both distinct and shared characteristics between the subtypes. Notably, two subtypes displayed opposite expression patterns for pathways involved in immune response alterations. In contrast, the third subtype exhibited a more unique profile characterized by increased expression of genes related to detoxification processes. All three subtypes showed a significant modulation of pathways related to the regulation of gene expression, metabolism, and cell signaling. ML revealed that the progression subtype with the worst prognosis can be predicted at baseline with 0.877 AUROC, yet the contribution of gene expression was marginal for the prediction of the subtypes.</p><p><strong>Conclusion: </strong>This study provides novel information regarding the transcriptomics profiles of PD progression subtypes, which may foster precision medicine with relevant indications for a finer-grained diagnosis and prognosis.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"17 ","pages":"11795735241286821"},"PeriodicalIF":2.6,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuroprotective potential of isofraxidin: Alleviating parkinsonian symptoms, inflammation and microglial activation. 异曲霉啶的神经保护潜力:减轻帕金森症状、炎症和小胶质细胞激活。
IF 2.6
Journal of Central Nervous System Disease Pub Date : 2025-01-09 eCollection Date: 2025-01-01 DOI: 10.1177/11795735241312661
Tin-An Wang, Shiao-Yun Li, Li-Yun Fann, I-Hsun Li, Tsung-Ta Liu, Hao-Yuan Hung, Chieh-Wen Chang, Chih-Chien Cheng, Ying-Che Huang, Pei-Yeh Yu, Jui-Hu Shih
{"title":"Neuroprotective potential of isofraxidin: Alleviating parkinsonian symptoms, inflammation and microglial activation.","authors":"Tin-An Wang, Shiao-Yun Li, Li-Yun Fann, I-Hsun Li, Tsung-Ta Liu, Hao-Yuan Hung, Chieh-Wen Chang, Chih-Chien Cheng, Ying-Che Huang, Pei-Yeh Yu, Jui-Hu Shih","doi":"10.1177/11795735241312661","DOIUrl":"10.1177/11795735241312661","url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD) is one of the most common neurodegenerative disorders. Previous research has confirmed that isofraxidin can reduce macrophage expression and inhibit peripheral inflammation. However, its effects on the central nervous system remain underexplored.</p><p><strong>Objective: </strong>This study aims to determine whether isofraxidin offers protective effects against PD.</p><p><strong>Methods: </strong>To assess the effects of isofraxidin, motor performance changes in LPS-induced PD mice were evaluated using rotarod, pole-climbing, and beam-walking tests. Striatal damage was examined through [<sup>18</sup>F]fluorodeoxyglucose ([<sup>18</sup>F]FDG) positron emission tomography (PET) imaging, and dopaminergic neurotoxicity was assessed using tyrosine hydroxylase (TH) staining. Microglial accumulation and activation were monitored with Iba-1 staining, while LPS-induced inflammation was examined via TNF-α and IL-1β staining.</p><p><strong>Results: </strong>Isofraxidin pre-treatment significantly improved LPS-induced motor dysfunction, as evidenced by better performance in the rotarod, pole-climbing, and beam-walking tests. [<sup>18</sup>F]FDG PET imaging showed that isofraxidin restored glucose uptake in the striatum, countering LPS-induced damage. Furthermore, Iba-1 staining revealed that isofraxidin markedly inhibited LPS-induced microglial activation and accumulation. TNF-α and IL-1β staining indicated a reduction in inflammation with isofraxidin treatment. Additionally, TH staining supported the neuroprotective role of isofraxidin on dopaminergic neurons.</p><p><strong>Conclusions: </strong>Isofraxidin exhibits notable neuroprotective properties by mitigating LPS-induced parkinsonian behaviors, microglial activation, inflammation, and dopaminergic neuron damage. These results highlight isofraxidin's potential as a therapeutic intervention for PD.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"17 ","pages":"11795735241312661"},"PeriodicalIF":2.6,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11713954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive insights of Sneddon syndrome: A clinical perspective. Sneddon综合征的综合见解:临床视角。
IF 2.6
Journal of Central Nervous System Disease Pub Date : 2024-12-19 eCollection Date: 2024-01-01 DOI: 10.1177/11795735241308767
Ahmad Yousef Alazzam
{"title":"Comprehensive insights of Sneddon syndrome: A clinical perspective.","authors":"Ahmad Yousef Alazzam","doi":"10.1177/11795735241308767","DOIUrl":"10.1177/11795735241308767","url":null,"abstract":"<p><strong>Background: </strong>Sneddon's syndrome is a rare thrombotic vasculopathy characterized by the coexistence of both cerebrovascular events and livedo reticularis.</p><p><strong>Objective: </strong>This review aims to raise awareness among physicians by discussing the whole clinical spectrum of the disease. Typically, Sneddon syndrome presents in middle-aged women with a cerebrovascular accident and a preexisting skin rash, which is livedo reticularis. Diagnosis is primarily clinical, relying on a high index of suspicion. Management focuses mainly on reducing the risk of cerebral infarctions and alleviating symptoms.</p><p><strong>Conclusion: </strong>Further research is necessary to better understand the disease's nature, which will contribute to improving early diagnosis and optimal management.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241308767"},"PeriodicalIF":2.6,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is transcranial direct current stimulation really beneficial for frontotemporal dementia? 经颅直流电刺激真的对额颞叶痴呆有益吗?
IF 2.6
Journal of Central Nervous System Disease Pub Date : 2024-12-18 eCollection Date: 2024-01-01 DOI: 10.1177/11795735241310126
Josef Finsterer
{"title":"Is transcranial direct current stimulation really beneficial for frontotemporal dementia?","authors":"Josef Finsterer","doi":"10.1177/11795735241310126","DOIUrl":"10.1177/11795735241310126","url":null,"abstract":"","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241310126"},"PeriodicalIF":2.6,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11656420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A narrative review of vagus nerve stimulation in stroke. 迷走神经刺激在中风中的叙事回顾。
IF 2.6
Journal of Central Nervous System Disease Pub Date : 2024-12-13 eCollection Date: 2024-01-01 DOI: 10.1177/11795735241303069
Yanhong Hu, Ruiqi Xiong, Suyue Pan, Kaibin Huang
{"title":"A narrative review of vagus nerve stimulation in stroke.","authors":"Yanhong Hu, Ruiqi Xiong, Suyue Pan, Kaibin Huang","doi":"10.1177/11795735241303069","DOIUrl":"10.1177/11795735241303069","url":null,"abstract":"<p><p>Stroke is a significant health concern impacting society and the health care system. Reperfusion therapy for acute ischemic stroke and standard rehabilitative therapies may not always be effective at improving post-stroke neurological function, and developing alternative strategies is particularly important. Vagus nerve stimulation (VNS) is a treatment option currently approved by the Food and Drug Administration (FDA) for intractable epilepsy, refractory depression, primary headache disorders, obesity, and moderate to severe upper-limb motor dysfunction in chronic ischemic stroke patients. Moreover, VNS has demonstrated potential efficacy in various conditions, including autoimmune diseases, disorders of consciousness, Alzheimer's disease, Parkinson's disease, traumatic brain injury, stroke, and other diseases. Although the popularity and application of VNS continue to increase rapidly, the field generally lacks a consensus on the optimal stimulation parameters. The stimulation parameters for VNS are directly related to the clinical outcome, and determining the optimal stimulation conditions for VNS has become an essential concern in its clinical application. This review summarizes the current evidence on VNS for stroke in preclinical models and clinical trials in humans, paying attention to the current types and stimulation parameters of VNS, highlighting the mechanistic pathways involved in the beneficial effects of VNS, critically evaluating clinical implementation challenges and proposing some suggestions for its future research directions. Achieving safe and effective clinical transformation of VNS requires further animal and clinical studies to determine the optimal stimulation parameters and therapeutic mechanisms.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241303069"},"PeriodicalIF":2.6,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11645777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Percutaneous spinal cord stimulation cylindrical lead placement for managing refractory neuropathic pain: A case series with an endoscopic-assisted approach. 经皮脊髓刺激圆柱形导联放置治疗难治性神经性疼痛:内窥镜辅助方法的病例系列。
IF 2.6
Journal of Central Nervous System Disease Pub Date : 2024-11-29 eCollection Date: 2024-01-01 DOI: 10.1177/11795735241302715
Zhouyang Hu, Hong Wang, Zhipeng Xu, Jianjin Zhang, Lijun Li, Guoxin Fan, Xiang Liao
{"title":"Percutaneous spinal cord stimulation cylindrical lead placement for managing refractory neuropathic pain: A case series with an endoscopic-assisted approach.","authors":"Zhouyang Hu, Hong Wang, Zhipeng Xu, Jianjin Zhang, Lijun Li, Guoxin Fan, Xiang Liao","doi":"10.1177/11795735241302715","DOIUrl":"10.1177/11795735241302715","url":null,"abstract":"<p><strong>Background: </strong>The paddle lead (PL) and cylindrical lead (CL) remain the main implant categories in spinal cord stimulation (SCS) for treating neuropathic pain. Surgeons often complain about the greater trauma associated with PL implantation, while percutaneous endoscopic technique offers a promising approach for minimizing the trauma associated to PL implantation. However, there remains a dearth of real-world case study on endoscopy-assisted CL implantation.</p><p><strong>Purpose: </strong>This study aimed to demonstrate the endoscopic-assisted approach and outcomes of CL implantation in SCS for managing neuropathic pain.</p><p><strong>Research design: </strong>A retrospective case series.</p><p><strong>Study sample: </strong>Patients aged 18 years and above with chronic neuropathic pain persisting for at least three months, refractory to standardized conservative treatment, were enrolled between January 2021 and March 2023.</p><p><strong>Data collection and analysis: </strong>The surgical key steps including puncture, working cannula placement, endoscopic laminotomy and endoscopic CL introduction were demonstrated. Characteristics as demographics, follow-up time, visual analog scale (VAS) score, pain disability index (PDI) score and patient-reported outcomes measurement information system (PROMIS) scale were assessed.</p><p><strong>Results: </strong>Successful CL implantation under endoscopy was achieved in all patients, including 3 with failed back surgery syndrome, 2 with complex regional pain syndrome and 2 with chronic pelvic pain. No spinal cord injuries, dural tears, lead migration, lead fractures, or postoperative infections were observed. VAS score of regional pain, PDI score as well as PROMIS of patient's quality of life were all significantly improved after surgery.</p><p><strong>Conclusion: </strong>Percutaneous endoscope-assisted CL implantation offered a new alternative technique for SCS in managing neuropathic pain.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241302715"},"PeriodicalIF":2.6,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of high-sensitivity cardiac troponin T with territorial middle cerebral artery brain infarctions and dynamic cerebral autoregulation. 高敏心肌肌钙蛋白 T 与大脑中动脉脑梗塞和动态大脑自调节的关系
IF 2.6
Journal of Central Nervous System Disease Pub Date : 2024-11-25 eCollection Date: 2024-01-01 DOI: 10.1177/11795735241302725
Manuel Bolognese, Laura Weichsel, Mareike Österreich, Martin Müller, Grzegorz Marek Karwacki, Lehel-Barna Lakatos
{"title":"Association of high-sensitivity cardiac troponin T with territorial middle cerebral artery brain infarctions and dynamic cerebral autoregulation.","authors":"Manuel Bolognese, Laura Weichsel, Mareike Österreich, Martin Müller, Grzegorz Marek Karwacki, Lehel-Barna Lakatos","doi":"10.1177/11795735241302725","DOIUrl":"10.1177/11795735241302725","url":null,"abstract":"<p><strong>Background: </strong>Cardiac high-sensitivity troponin T (hs-cTnT) is linked to the cardioembolic origin, severity, and outcome of acute ischemic stroke. Furthermore, larger brain infarctions are often accompanied by impaired dynamic cerebral autoregulation (dCA), which is also indicative of a poor prognosis.</p><p><strong>Objectives: </strong>This study aimed to investigate whether hs-cTnT levels can serve as a predictor of dCA impairment.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>In 330 consecutive patients with stroke (age 71 years [IQR 59-78]; 100 women; 229 territorial and 111 non-territorial brain infarcts) with successful dCA assessment, hs-cTnT levels were measured within 24 hours of stroke onset. These measurements were analyzed in relation to cerebrovascular risk factors, stroke origin, stroke severity (National Institute of Health Stroke Scale, NIHSS at entry), modified Rankin scale (mRs) at 3 months, and stroke volume determined by cranial computed tomography perfusion (CTP). dCA was assessed using transfer function analysis, which assessed the relationship between middle cerebral artery blood flow velocity and blood pressure. Coherence, gain, and phase were estimated across 3 frequency ranges: very low (0.02-0.07 Hz), low (0.07-0.15 Hz), and high (0.15-0.5 Hz).</p><p><strong>Results: </strong>In univariate analysis, hs-cTnT was associated with cardioembolism and territorial infarction. In the multinomial logistic regression analysis, independent risk factors for the presence of a territorial infarction included atrial fibrillation, the NIHSS score, the infarct core on CTP, cardioembolism, and large vessel disease, but not hs-cTnT levels. Risk factors for a poor outcome (mRs >2) included age, hs-cTnT, and NIHSS score. Overall, the coherence, gain, and phase were not predicted by hs-cTnT levels.</p><p><strong>Conclusions: </strong>Hs-cTnT levels are associated with poor stroke outcomes. However, they do not predict dCA impairment.</p><p><strong>Registration: </strong>ClinicalTrials.gov NCT04611672, 11.10.2020.</p>","PeriodicalId":15218,"journal":{"name":"Journal of Central Nervous System Disease","volume":"16 ","pages":"11795735241302725"},"PeriodicalIF":2.6,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11590146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信